Nuvectis Pharma (NVCT) Stock Price, News & Analysis

Company Overview

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders. Lead candidates are being evaluated for inherited conditions characterized by enzyme deficiencies or receptor dysfunction, with the goal of delivering active protein payloads directly to affected cells. In parallel, the company is exploring applications of its delivery technology in areas such as oncology and inflammatory disease, seeking strategic partnerships to advance select programs into later clinical development.

Headquartered in San Diego, California, Nuvectis Pharma operates with a management team drawn from established life-science and pharmaceutical backgrounds. The company maintains research collaborations with academic centers and contract development organizations to accelerate its discovery and development activities. With a focus on rare diseases and high-unmet-need patient populations, Nuvectis is positioning its platform to address therapeutic challenges that extend beyond the reach of conventional biologic and small-molecule approaches.

Key Stats

• Today's Range: $6.45 to $6.73
• 50-Day Range: $6.00 to $8.28
• 52-Week Range: $4.44 to $11.80
• Volume: 50,730 shs
• Average Volume: 70,176 shs
• Market Capitalization: $170.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.33
• Consensus Rating: Buy

Nuvectis Pharma Stock Analysis - MarketRank™

Nuvectis Pharma scored higher than 65% of companies evaluated by MarketBeat, and ranked 366th out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Nuvectis Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Nuvectis Pharma has a consensus price target of $15.33, representing about 129.5% upside from its current price of $6.68.

Amount of Analyst Coverage

Nuvectis Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nuvectis Pharma are expected to grow in the coming year, from ($1.01) to ($0.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuvectis Pharma is -5.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuvectis Pharma is -5.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuvectis Pharma has a P/B Ratio of 13.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.37% of the float of Nuvectis Pharma has been sold short.

Short Interest Ratio / Days to Cover

Nuvectis Pharma has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Nuvectis Pharma has recently decreased by 3.77%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuvectis Pharma does not currently pay a dividend.

Dividend Growth

Nuvectis Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.37% of the float of Nuvectis Pharma has been sold short.

Short Interest Ratio / Days to Cover

Nuvectis Pharma has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Nuvectis Pharma has recently decreased by 3.77%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 1.00

News Sentiment

Nuvectis Pharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Nuvectis Pharma this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added Nuvectis Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Nuvectis Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $314,300.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

30.52% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NVCT Stock Analysis - Frequently Asked Questions

How have NVCT shares performed this year?

Nuvectis Pharma's stock was trading at $5.41 at the beginning of 2025. Since then, NVCT stock has increased by 23.5% and is now trading at $6.68.

How were Nuvectis Pharma's earnings last quarter?

Nuvectis Pharma, Inc. (NASDAQ:NVCT) posted its earnings results on Tuesday, August, 5th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.05.

When did Nuvectis Pharma IPO?

Nuvectis Pharma (NVCT) raised $19 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 3,200,000 shares at a price of $5.00-$7.00 per share.

Who are Nuvectis Pharma's major shareholders?

Top institutional investors of Nuvectis Pharma include Baldwin Wealth Partners LLC MA (1.68%), Geode Capital Management LLC (1.37%), Marshall Wace LLP (0.25%) and Austin Wealth Management LLC (0.10%). Insiders that own company stock include Marlio Charles Mosseri, Enrique Poradosu and Shay Shemesh.
View institutional ownership trends.

How do I buy shares of Nuvectis Pharma?

Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nuvectis Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvectis Pharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/07/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NVCT
• CIK: 1875558
• Web: www.nuvectis.com
• Phone: 201-614-3150
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Nuvectis Pharma: $15.33
• High Price Target: $19.00
• Low Price Target: $10.00
• Potential Upside/Downside: +129.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -150.81%
• Return on Assets: -94.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.66
• Quick Ratio: 2.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.50 per share
• Price / Book: 13.36

Miscellaneous

• Outstanding Shares: 25,460,000
• Free Float: 17,688,000
• Market Cap: $170.07 million
• Optionable: Not Optionable
• Beta: -0.27